Ironwood Pharma (IRWD) Completes Merger With VectivBio
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
December 12, 2023 4:01 PM ESTBOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Ironwood) (Nasdaq: IRWD), a GI-focused healthcare company, today announced the successful completion of the squeeze-out merger under Swiss law (the Squeeze-Out Merger) pursuant to which VectivBio Holding AG (VectivBio) has been merged with and into Ironwood Pharmaceuticals GmbH (Merger Sub), a wholly-owned subsidiary of Ironwood organized under the laws of Switzerland. As a result of the Squeeze-Out Merger, all remaining outstanding ordinary shares of VectivBio not previously purchased by Ironwood have been cancelled and converted into the right to receive $17.00 per share in cash, subject to any applicable withholding taxes. The... More



